Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Related Articles by Review for PubMed (Select 20884247)

1.

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2.

PMID:
20884247
2.

Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM.

Int J Cancer. 2009 May 15;124(10):2416-29. doi: 10.1002/ijc.24202. Review.

3.

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.

Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H.

J Steroid Biochem Mol Biol. 2013 Nov;138:248-56. doi: 10.1016/j.jsbmb.2013.06.002. Epub 2013 Jun 20. Review.

5.

Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

Aggarwal RR, Ryan CJ, Chan JM.

Urol Oncol. 2013 Jul;31(5):522-30. doi: 10.1016/j.urolonc.2011.05.001. Epub 2011 Jun 12. Review.

PMID:
21658978
6.

Determination of IGFs and their binding proteins.

Hjortebjerg R, Frystyk J.

Best Pract Res Clin Endocrinol Metab. 2013 Dec;27(6):771-81. doi: 10.1016/j.beem.2013.08.010. Epub 2013 Sep 6. Review.

PMID:
24275189
7.

Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.

Bitting RL, Armstrong AJ.

Cancer J. 2013 Jan-Feb;19(1):25-33. doi: 10.1097/PPO.0b013e31827e0b9c. Review.

PMID:
23337754
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk